Medical network on April 13 - Shanghai kerui group parent company alex's 9.7 billion acquisition of Germany biotechnology company Pan Biotech, refresh the Chinese pharmaceutical industry to sea trading records blazes did not disappear, Shanghai alex's 2016 annual report last night, 69.34% of the net profit margin industry attention again. As domestic blood products industry leader, Shanghai alex always do well, and from income, net profit, plasma acquisition ability and product line analysis of several domestic large blood product giant, as can be seen as productive resources concentrated to large enterprises, blood products industry the stronger the strong trend becomes clear. 

 

Shanghai transcript: alex's net profit margin of 69.34% 

 

On the evening of April 11 Shanghai alex released 2016 annual report, its in the past year to achieve the business income is 2.326 billion yuan, up 15.54%; Net profit attributable to shareholders of listed companies of 1.613 billion yuan, up 11.84% from a year earlier. Net profit margin of 69.34%. 

 

Compared with 2015, the revenue and profit growth rate have larger decline - 2015, the growth rate of 52.55% and 182.35% respectively. The reason is that alex completed in 2014 in Shanghai to zhengzhou and alex's way of mergers and acquisitions, increased blood product categories to 11, improve the utilization rate of the plasma, net profit also increased. 

 

In recent five year Shanghai alex's operating income and net profit (unit: one hundred million yuan) 

 

 

Shanghai alex for its 2016 earnings growth situation, shown on the annual report for the following points: 

 

1. Plasma station layout. Look from its annual report, the current Shanghai alex and its subsidiaries (zhengzhou, alex's way, and zhejiang hai kang) with single plasma stand 35 (including two under construction), mining slurry range of guangxi, hunan, hainan, shaanxi, anhui, guangdong, Inner Mongolia, zhejiang, hubei, jiangxi 10 provinces (autonomous regions), mining slurry capacity of nearly nine hundred tons. 

 

2. The plasma utilization rate is high, the product variety is complete. Shanghai alex is the present domestic a few can be extracted from plasma blood products manufacturing enterprises, one of the six components are of clotting co-stimulating products is one of the most complete production enterprises, now has 11 species of blood products products. By improving the technology level, increase the output of the original unit of the plasma sheet product, improve the utilization rate of plasma products more units and thus reducing the production cost, with advantage and competitiveness. 

 

3. Drive m&a integration. Alex was completed in 2014 in Shanghai to zhengzhou and alex's way of mergers and acquisitions, a wholly owned subsidiary in 2016 with the same way of zhejiang sea kang 90.00% stake. Zhengzhou alex in a single slurry station mining scale, mining slurry ability have good experience and production of fine management; In the same way station management, product yield, exemption product has advantages such as; Zhejiang sea, as the only blood products enterprises in zhejiang province, has a certain geographical advantages. After the merger integration, Shanghai alex in the slurry station management, production management, purchasing and sales channel management is improved. 

 

From the point of the current momentum of development, Shanghai alex will maintain stable growth. And recent reports that the German manufacturers of plasma products Biotest agreed to kerui group (one of Shanghai's alex's actual controlling shareholders) is put forward, including debt, value $1.4 billion (about $9.66 billion) takeover. Biotest products are mainly used in the treatment of blood coagulation disorders, autoimmune diseases and immune deficiency, etc. If the merger is successful, Shanghai alex will undoubtedly expanded scale, stabilize its leading position. 

 

Four big domestic blood giant lateral comparison 

 

Since 2015, when the price after let go, in 3 d interactive, under the background of health charged fees, the pharmaceutical industry growth is slowing, but so is quantity and price, blood products industry business degrees higher, entered the golden period of development. As each big drug firms have announced 2016 transcripts, development situation of the blood products biggest will show up in the 2016 annual report. It can be seen that as domestic 2001 is no longer a new batch of blood products production enterprise, small business development is limited by a variety of industry policy, production resources concentrated to large enterprises, is expected to be as foreign appear the situation of the strong stronger. 

 

Below will choose Shanghai, made by hualan bio-engineering, alex's tiantan biological and bm four a-share listed hematic products giant enterprises are analyzed. 

 

Income ability contrast 

 

Four big blood product enterprises operating income contrast (unit: one hundred million yuan) 

 

 

Comparing four giant of blood products, it can be seen on the revenue, Shanghai alex's revenue, is ahead and boya creature is relatively weak, it is also because of the influence of the enterprise scale, enterprise scale, blood stations and sales rolled out relatively wide range, operating income will rise. But in terms of revenue growth, 2015 Shanghai alex leading, may be due to the merger and acquisition the scale expansion of zhengzhou and alex's creatures with the same way, but in 2016 achievement view, made by hualan bio-engineering growth rate of 31.45% in the four best blood products in the enterprise performance and according to its annual report, the reason is that made by hualan bio-engineering is highest plasma comprehensive utilization in blood products industry in China, most varieties, the most complete specifications of the enterprise. 

 

Net profit compared 

 

The big four blood product enterprise net profit contrast (unit: one hundred million yuan) 

 

 

Above the net profit attributable to shareholders of listed companies, Shanghai alex's net profit is much higher than the other three, its blood is the industry leading position is very stable. Since Shanghai's acquisition way alex's biological blood product categories from 7 to 11, improve the utilization rate of the plasma, net profit also increased. 

 

Acquisition of the plasma 

 

Four large amount of blood products enterprises adopt plasma contrast (in tons) 

 

 

From the point of mining slurry amount, made by hualan bio-engineering to 2016 mining slurry capacity is 1030 tons at the top of the list, and its growth rate is also very bright eye, in mining slurry ability show better competition. And slurry station from 2016 approved, in 2016 the industry increased plasma stand number 20, among them, the Shanghai three, alex's made by hualan bio-engineering three, two, the temple of heaven biological boya biological 2, it seems that made by hualan bio-engineering will continue to maintain the leading position in plasma volume. 

 

The tremendous amount of the product line 

 

Domestic industry main blood products enterprise product distribution (2016) 

 

 

Can see alex are made by hualan bio-engineering and Shanghai has the most complete domestic product separation ability, in terms of time, give a slight edge to made by hualan bio-engineering, management is relatively mature. 

 

future 

 

Demand contradiction in the next few years, blood products industry will continue to exist, the boom of industry is higher, and the medicine price system fully liberalised, pulp stand approval to speed up, expanding coverage and dividend policy of gradually released, blood products industry will continue to maintain sustained and rapid and stable growth in the future. 

 

But on the other hand, also pointed out that industry professionals, as the contradiction between supply and demand of domestic gradually ease, the focus of the domestic enterprise competition will be controlled by plasma resources, gradually turned to technology competition, to adopt new technology for improving the utilization ratio of the plasma or launch new products of enterprises will be.